Mr. Mike Dethick, Managing Director, R&D-based Pharmaceutical Association Committee (RDPAC) China, introduced the opportunities and challenges of regulatory policy on drug traceability, and the existing problems on China’s electronic drug supervision system. Mr. Dethick emphasised that global standards, including drug tracking and tracing, could offer a range of benefits, especially increased patient safety and supply chain efficiency.
Mr. Dethick also shared the preliminary recommendations from the RDPAC that included enhancing the responsibilities of drug manufacturers and mobilisation of social resources for the supervision of drug safety.
Additional recommendations included acceptance and adoption of the electronic supervision of barcoding in line with international practices, encouraging the use of international standards, yet, allowing the manufacturer to choose international standards or the China’s electronic barcode.
Thirdly, the RDPAC recognises the importance of database management, using the database owned by the manufacturer or the volunteering third party selected by manufacturer and ensuring compatibility of the China electronic barcode with international standards.
Additional information can be found in this presentation.